Looking back on dental equipment & technology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Envista (NYSE: NVST) and its peers.

The dental equipment and technology industry encompasses companies that manufacture orthodontic products, dental implants, imaging systems, and digital tools for dental professionals. These companies benefit from recurring revenue streams tied to consumables, ongoing maintenance, and growing demand for aesthetic and restorative dentistry. However, high R&D costs, significant capital investment requirements, and reliance on discretionary spending make them vulnerable to economic cycles. Over the next few years, tailwinds for the sector include innovation in digital workflows, such as 3D printing and AI-driven diagnostics, which enhance the efficiency and precision of dental care. However, headwinds include economic uncertainty, which could reduce patient spending on elective procedures, regulatory challenges, and potential pricing pressures from consolidated dental service organizations (DSOs).

The 4 dental equipment & technology stocks we track reported a strong Q4. As a group, revenues beat analysts’ consensus estimates by 4.7% while next quarter’s revenue guidance was in line.

In light of this news, share prices of the companies have held steady as they are up 3.9% on average since the latest earnings results.

Best Q4: Envista (NYSE: NVST)

Uniting more than 30 trusted brands including Nobel Biocare, Ormco, and DEXIS under one corporate umbrella, Envista Holdings (NYSE: NVST) is a global dental products company that provides equipment, consumables, and specialized technologies for dental professionals.

Envista reported revenues of $750.6 million, up 15% year on year. This print exceeded analysts’ expectations by 10.6%. Overall, it was a stunning quarter for the company with an impressive beat of analysts’ revenue and full-year EPS guidance estimates.

"With our disciplined focus on Growth, Operations, and People, Q4 2025 marked another quarter of continued progress for Envista," said Paul Keel, CEO.

Envista scored the biggest analyst estimates beat and fastest revenue growth of the whole group. Unsurprisingly, the stock is up 7.6% since reporting and currently trades at $26.60.

Is now the time to buy Envista? Access our full analysis of the earnings results here, it’s free.

Henry Schein (NASDAQ: HSIC)

With a vast inventory of over 300,000 products stocked in distribution centers spanning more than 5.3 million square feet worldwide, Henry Schein (NASDAQ: HSIC) is a global distributor of healthcare products and services primarily to dental practices, medical offices, and other healthcare facilities.

Henry Schein reported revenues of $3.44 billion, up 7.7% year on year, outperforming analysts’ expectations by 2.8%. The business had a strong quarter with a solid beat of analysts’ revenue estimates.

Although it had a fine quarter compared its peers, the market seems unhappy with the results as the stock is down 3.8% since reporting. It currently trades at $77.54.

Is now the time to buy Henry Schein? Access our full analysis of the earnings results here, it’s free.

Slowest Q4: Dentsply Sirona (NASDAQ: XRAY)

With roots dating back to 1877 when it introduced the first dental electric drill, Dentsply Sirona (NASDAQ: XRAY) manufactures and sells professional dental equipment, technologies, and consumable products used by dentists and specialists worldwide.

Dentsply Sirona reported revenues of $961 million, up 6.2% year on year, exceeding analysts’ expectations by 4.2%. Still, it was a softer quarter as it posted full-year revenue and EPS guidance missing analysts' estimates.

As expected, the stock is down 5.1% since the results and currently trades at $12.09.

Read our full analysis of Dentsply Sirona’s results here.

Align Technology (NASDAQ: ALGN)

Pioneering an alternative to traditional metal braces with nearly invisible plastic aligners, Align Technology (NASDAQ: ALGN) designs and manufactures Invisalign clear aligners, iTero intraoral scanners, and dental CAD/CAM software for orthodontic and restorative treatments.

Align Technology reported revenues of $1.05 billion, up 5.3% year on year. This number beat analysts’ expectations by 1.2%. It was a strong quarter as it also produced a beat of analysts’ EPS and revenue estimates.

Align Technology had the weakest performance against analyst estimates and slowest revenue growth among its peers. The stock is up 16.9% since reporting and currently trades at $187.30.

Read our full, actionable report on Align Technology here, it’s free.

Market Update

Late in 2025 into early 2026, there was hand wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?

These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.

Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.